The Vision: GTx hopes that the highly-anticipated ASTRID Trial results this Fall will be similar to the proof-of-concept data unveiled a year ago in which:
• Mean stress leaks decreased by 81% from baseline over the 12-week treatment period
(reductions in stress leaks/day of ≥ 50% from baseline are considered clinically significant)
• One-third of women continued to be essentially dry 7-months post-treatment
The Milestone: Early Q4 2018, GTx (NASDAQ:GTXI) plans to report results from a placebo-controlled clinical trial (the ASTRID Trial) to evaluate whether its drug (a daily pill called enobosarm) may be “kegels in a bottle”, as characterized early-on by principal investigator, Ken Peters, M.D., Chairman of Urology, Oakland University William Beaumont School of Medicine.
The ASTRID Trial: A Phase 2 double-blind, placebo-controlled clinical trial of orally-administered enobosarm (3 mg or 1 mg) in 493 post-menopausal women with SUI. ASTRID is evaluating whether enobosarm, administered daily for 12 weeks, significantly improves stress leaks, compared to placebo.
Watch: “Kegels In A Bottle”: Preliminary Results Of A Selective Androgen Receptor Modulator For The Treatment Of SUI - Kenneth Peters
Watch: Enobosarm in Postmenopausal Women for Stress Urinary Incontinence - Interview with Kenneth Peters